CSL shares have seen a significant downturn due to recent challenges, yet analysts see potential for recovery, with a projected rebound to $275, driven by its strong foundation and global healthcare ...
Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom ...
Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data proving the treatment’s benefits remain durable after five years. The five-year ...
A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount. CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and ...
The Walmart-exclusive Icon Blue DualSense Controller is back in stock and on sale for $64 (was $85). Launched in October, this eye-catching edition of the official PlayStation controller was first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback